毛利率80%算啥!这3家药企已超90%

  • 药企,营业收入,毛利率
  • 米内网/林晓



日前,上市公司2016年半年度报告已经披露完毕,毛利率超过90%的上市公司有15家,其中3家是药企,占比达20%,此外,有8家药企毛利率超过80%。






我武生物

营业收入:13341.56万元,净利润:5412.94万元

毛利率:95.50%,净利率:40.57%

主要产品:粉尘螨滴剂


上半年我武生物实现营业收入13341.56万元,同比增长13.27%,营业利润6368.31万元,同比增长9.96%;归属于上市公司普通股股东的净利润5412.94万元,同比增长5.45%。业绩增长的主要因素是随着社会工业化的深入和人们生活方式的改变,过敏性疾病患病率持续增高,国内过敏性疾病市场规模不断扩大。


我武生物是一家以变应原制品的研发、生产和销售为主营业务的生物制药类企业,已经获准上市的产品包括“粉尘螨滴剂”(商品名:畅迪)和“粉尘螨皮肤点刺诊断试剂盒”(商品名:畅点)。“粉尘螨滴剂”用于粉尘螨过敏引起的过敏性鼻炎、过敏性哮喘的脱敏治疗,该产品用于粉尘螨过敏引起的特应性皮炎的临床试验正在进行中。


为了增强竞争力,我武生物在产品研发方面,黄花蒿粉滴剂、尘螨合剂及粉尘螨滴剂治疗成人特应性皮炎的临床试验,黄花蒿花粉点刺液等9项产品的临床申报工作,丰富了自身在过敏领域的产品结构。


舒泰神

营业收入:61857.78万元,净利润:11835.97万元

毛利率:94.49%,净利率:19.13%

主要产品:苏肽生、舒泰清


舒泰神2016年上半年实现营业收入61857.78万元,同比增长10.65%;营业利润14117.58万元,归属上市公司股东的净利润11835.97万元,同比增长8.30%。舒泰神主要产品销量较去年同期稳步提升,营业收入稳步提高。此外,加快推进研发项目进展、研发体系系统能力建设,研发投入大幅上扬。


注射用鼠神经生长因子“苏肽生”和复方聚乙二醇电解质散(Ⅳ)“舒泰清”是舒泰神的主要产品,目前这两个产品均已进入国家级、全部省级“基本医疗保险、工伤保险和生育保险药品目录”。苏肽生的销售收入为54190.69万元,同比增长9.27%;舒泰清的销售收入为7600.54万元,同比增长22.14%。销售收入增长主要是因为不断强化市场工作,提高产品策划和学术推广水平,提高品牌和产品的知名度、治疗地位;深入开发现有覆盖医院,进一步拓展未开发医院;优化销售效率,进一步提升营销人员的能力素质与绩效结果。除上述两个产品之外,舒泰神还生产曲司氯铵胶囊、阿司匹林肠溶片、萘丁美酮胶囊等。


值得一提的是,苏肽生是舒泰神营业收入的主要来源,如果苏肽生客观经营环境发生重大变化、销售产生波动,将对其经营业绩和财务状况产生不利影响。因此,舒泰神优化另一重要产品舒泰清的产品定位及营销思路,大力提高该产品市场覆盖的广度与深度;同时,积极推动新产品曲司氯铵胶囊的招投标和市场推广工作。而在研发方面,集中力量推进重点研发项目的进度,加快推进新产品上市。



智飞生物

营业收入:18394.40万元,净利润:1203.89万元

毛利率:91.01%,净利率:6.54%

主要产品:自主研发生产的二类疫苗


上半年,智飞生物营业收入18394.40万元,净利润1203.89万元。主营业务收入主要来自二类疫苗的销售,尤其是自主研发生产的二类疫苗。疫苗与治疗性生物制品占总营业收入的99.66%,自主研发生产的二类疫苗收入占总营业收入的91.80%,代理的二类苗营业收入占总营业收入的1.02%。值得一提的是,受行业内不可抗力事件影响,智飞生物2016上半年疫苗销售额大幅下降,同比下降52.17%,自主产品的销售收入同比下降20.40%;自主产品的毛利率同比下降1.87%,综合毛利率同比增加20.51%,主要是因为代理产品减少,成本降低。


智飞生物主要在售的产品包括AC-Hib三联疫苗、AC结合疫苗、ACYW135流脑多糖疫苗、b型流感嗜血杆菌结合疫苗、注射用母牛分枝杆菌(微卡)等品种。


智飞生物旗下有四家全资子公司,智飞绿竹主要从事以预防脑膜炎、肺炎为主的细菌性疫苗产品的研发、生产和销售;智飞龙科马主要从事防治结核病类生物制品及病毒类疫苗的研发、生产和销售;重庆智仁主要从事疫苗销售,产品业务可延伸至一般药品领域;智飞香港主要从事生物制品的销售推广、进出口贸易,生物技术合作、引进及出售,对外投融资业务等。




This link:http://www.chemcd.com/news/32118.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.